Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN

Martin Zenke, Steffen Koschmieder

Blood (2025) 146 (20): 2377–2378.

https://doi.org/10.1182/blood.2025030551

Published: 2025

Journal Articles

Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN

Blood (2025) 146 (Supplement 1): 1493.

https://doi.org/10.1182/blood-2025-1493

Published: 2025

Journal Articles

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Veronika Buxhofer-Ausch, Andreas Reiter, Ciprian Tomuleasa, Albert Woelfler, Lino Teichmann, Luminita Ocroteala, Krauth Maria-Theresa, Charu Charu, Stefanie Schlager, Victoria Empson, Christoph Klade, Kurt Krejcy, Heinz Gisslinger, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 2032.

https://doi.org/10.1182/blood-2025-2032

Published: 2025

Journal Articles

The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)

Blood (2025) 146 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2025-1453

Published: 2025

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Blood (2025) 146 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2025-1021

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib, Claire Harrison, John Mascarenhas, Erin Crowgey, Betty Lamothe, Chenwei Tian, Evan Braunstein, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 71.

https://doi.org/10.1182/blood-2025-71

Published: 2025

Journal Articles

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

Brandi Reeves, Marcelo Szymanski de Toledo, Fatima Trebak, Malgorzata Kasztan, Vimal Derebail, Rafal Pawlinski, Steffen Koschmieder, J.E. Hamer-Maansson, Ahmad Naim, Valkal Bhatt

Blood (2025) 146 (Supplement 1): 605.

https://doi.org/10.1182/blood-2025-605

Published: 2025

Journal Articles

Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial

Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, Martin Griesshammer, Katja Sockel, Regina Herbst, Claudia Wickenhauser, Haifa Kathrin Al-Ali

Blood (2025) 146 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2025-3804

Published: 2025

Journal Articles

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Juan Carlos Hernandez Boluda, Catherine Ellis, Tom (sizhu) Liu, Shiyuan Zhang, Jessica Lim, Dwaipayan Patnaik, Vikas Gupta

Blood (2025) 146 (Supplement 1): 5581.

https://doi.org/10.1182/blood-2025-5581

Published: 2025

Journal Articles

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40

Blood blood.2025028489.

https://doi.org/10.1182/blood.2025028489

Published: 2025

Includes: Supplemental data

Journal Articles

ZIP10 (SLC39A10) Is an Important Transport Protein in Acute Myeloid Leukemia

Benjamin Rolles, Nicolas Chatain, Richard Görg, Margherita Vieri, Nora Tillmann-Tröster, Marcel G. Bourgeois, Deborah Christen, Jeanette Walter, Addison Clare Hillerbrandt, Kyle A. Romine, Kathryn Taylor, Jens Bertram, Edgar Jost, Steffen Koschmieder, Fabian Beier, Maximilian Stahl, Tim H. H. Brummendorf, Lothar Rink, Inga Wessels

Blood (2024) 144 (Supplement 1): 5737.

https://doi.org/10.1182/blood-2024-203860

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

Blood (2024) 144 (Supplement 1): 406.

https://doi.org/10.1182/blood-2024-206143

Published: 2024

Journal Articles

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

Monia Marchetti, Alessandro Maria Vannucchi, John O. Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Robert Peter Gale, Claire Harrison, Rüdiger Hehlmann, Jean-Jacques Kiladjian, Steffen Koschmieder, Ruben Mesa, Francesco Passamonti, Alessandro Rambaldi, Ayalew Tefferi, Tiziano Barbui

Blood (2024) 144 (Supplement 1): 7898.

https://doi.org/10.1182/blood-2024-198646

Published: 2024

Journal Articles

CSF3R T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

Alessandra Hartke, Julia Klotz, Axel Künstner, Anke Fähnrich, Hauke Busch, Timo Gemoll, Jasmin Osius, Steffen Koschmieder, Tim H. H. Brummendorf, Heike L. Pahl, Florian H. Heidel, Konstanze Döhner, Martin Griesshammer, Andreas Reiter, Justus Duyster, Nikolas C. C. von Bubnoff, Sivahari P. Gorantla

Blood (2024) 144 (Supplement 1): 1348.

https://doi.org/10.1182/blood-2024-202513

Published: 2024

Journal Articles

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Blood (2024) 144 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2024-208687

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hijack the HiJAKer: rethinking therapy for JAK2-mutant MPN

Liposomal melatonin targets mutant hematopoiesis and bone marrow remodeling in MPN

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial

Impact of hemoglobin improvement with momelotinib on survival in patients with myelofibrosis and anemia: Post hoc analyses of the simplify-1 and momentum trials

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40

ZIP10 (SLC39A10) Is an Important Transport Protein in Acute Myeloid Leukemia

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)

New Criteria for Evaluating Outcomes of Myelofibrosis Therapy

CSF3R T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only